Menu Search
Equities

Theralase Technologies Inc

TLT:CVE

Theralase Technologies Inc

Actions
Health CareMedical Equipment and Services
  • Price (CAD)0.285
  • Today's Change0.000 / 0.00%
  • Shares traded34.04k
  • 1 Year change+67.65%
  • Beta1.3490
Data delayed at least 15 minutes, as of Nov 14 2024 19:44 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in CAD

The one analyst offering a 12 month price target expects Theralase Technologies Inc share price to rise to 0.80 in the next year from the last price of 0.285.
High180.7%0.80
Med180.7%0.80
Low180.7%0.80

Earnings history & estimates in CAD

On Aug 12, 2024, Theralase Technologies Inc reported 2nd quarter 2024 losses of -0.005 per share. This result was in line with the expectation of the one analyst following the company and was the same as last year's 2nd quarter results.
The next earnings announcement is expected on Nov 27, 2024.
Average growth rate-0.83%
Theralase Technologies Inc reported annual 2023 losses of -0.022 per share on Mar 27, 2024.
Average growth rate+14.73%
More ▼

Revenue history & estimates in CAD

Theralase Technologies Inc. had 2nd quarter 2024 revenues of 101.00k. The one analyst following the company did not expect it to generate revenues. This was 51.21% below the prior year's 2nd quarter results.
Average growth rate-9.15%
Theralase Technologies Inc. had revenues for the full year 2023 of 1.07m. This was 6.06% below the prior year's results.
Average growth rate+5.07%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.